At a glance
- SHLP2 is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 26 publications mentioning it, including 0 randomized controlled trials and 4 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Mitochondrial-derived peptides in female reproduction: Emerging regulators of oocyte competence and novel therapeutic opportunities for infertility.
- Mitochondrial Peptide SHLP2 Limits Poly(I: C)-Induced Alveolar Epithelial Injury by Modulating Redox, Apoptotic, Inflammatory, and Inflammasome Responses.
- Altered placental expression of small humanin-like peptides in gestational diabetes mellitus.
- Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.
- Mitochondrial-derived microproteins in cancer and neurodegeneration: A new era of cross-disease mechanistic insights.
- SHLP2 restores pre-osteoblastic cells against oxidative stress-induced inflammaging.
- SHLP2 alleviates allergic asthma by inhibiting ETV5/GSDMD signaling pathway-mediated pyroptosis.
- Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
- A naturally occurring variant of SHLP2 is a protective factor in Parkinson's disease.
- Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.